Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways

2006 Annual Review of Immunology 982 citations

Abstract

Resolution of inflammation and the return of tissues to homeostasis are essential. Efforts to identify molecular events governing termination of self-limited inflammation uncovered pathways in resolving exudates that actively generate, from essential omega fatty acids, new families of local-acting mediators. These chemical mediator families, termed resolvins and protectins, are potent stereoselective agonists that control the duration and magnitude of inflammation, joining the lipoxins as signals in resolution. This review examines the mapping of these circuits and recent advances in our understanding of the biosynthesis and actions of these novel proresolving lipid mediators. Aspirin jump-starts resolution by triggering biosynthesis of specific epimers of these mediators. In addition to their origins in inflammation resolution, these compounds also display potent protective roles in neural systems, liver, lung, and eye. Given the potent actions of lipoxins, resolvins, and protectins in models of human disease, deficiencies in resolution pathways may contribute to many diseases and offer exciting new potential for therapeutic control via resolution.

Keywords

Lipid signalingInflammationBiologyLipoxinImmunologyNeuroscience

MeSH Terms

AnimalsDisease ModelsAnimalDocosahexaenoic AcidsHumansInflammationInflammation MediatorsLipoxinsOrgan SpecificitySignal Transduction

Affiliated Institutions

Related Publications

Publication Info

Year
2006
Type
review
Volume
25
Issue
1
Pages
101-137
Citations
982
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

982
OpenAlex
42
Influential
810
CrossRef

Cite This

Charles N. Serhan (2006). Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annual Review of Immunology , 25 (1) , 101-137. https://doi.org/10.1146/annurev.immunol.25.022106.141647

Identifiers

DOI
10.1146/annurev.immunol.25.022106.141647
PMID
17090225

Data Quality

Data completeness: 81%